International Journal of Pharmacology and Clinical Research (IJPCR)

IJPCR |Vol.9 | Issue 1 | Jan - Mar -2025

www.ijpcr.com

ISSN: 2349-5448

DOI : https://doi.org/10.61096/ijpcr.v9.iss1.2025.39-49

Review

Microbiome Dynamics: Impacts On Health, Disease And Future Therapeutic Approaches

Irulappan. K*, Karpagam Kumara Sundari. S, Shamalar. S

Department of Pharmacology, Periyar College of Pharmaceutical Sciences, Trichy-620021, Tamil Nadu, India.

Corresponding Author: Irulappan. K
Email: irulappankarthi12@gmail.com

Published on: 23 Feb 2025

Published by:
DrSriram Publications

Abstract

The human microbiome, a dynamic and complex ecosystem of microorganisms living on and within the body, is increasingly recognized for its critical role in health and disease. This paper investigates the diverse functions of the microbiome, particularly its contributions to metabolic processes, immune system modulation and the development of various diseases. A significant focus is placed on the gut microbiome's influence on digestion, vitamin production and overall systemic health through metabolites like short-chain fatty acids. The skin, oral and urinary microbiomes are also explored for their contributions to disease prevention and immune function. The review provides a historical perspective on microbiome research, emphasizing the impact of advancements in metagenomics, metatranscriptomics and metabolomics on our understanding of these microbial communities. Despite considerable progress, challenges persist in applying microbiome research to therapeutic contexts, given the complexity of microbial ecosystems, individual variability and technical limitations. The potential of microbiome-based therapies, such as probiotics and fecal microbiota transplants, in treating conditions ranging from gastrointestinal disorders to mental health issues is highlighted, alongside a discussion on the ethical implications of microbiome research. The paper concludes by discussing the role of personalized medicine, microbiome-based therapeutic discoveries and AI- driven microbiome sequencing in future treatments.

Keywords: Microbiome, Metagenomics, Therapeutic innovation, Probiotic, Microbial ecosystem

INTRODUCTION

The gut microbiome aids in the digestion of complex carbohydrates and synthesizes important vitamins, including vitamin K and several B vitamins.[1] Microbial metabolism produces short- chain fatty acids (SCFAs), including butyrate, propionate, and acetate. SCFAs impact systemic metabolism and are essential for preserving intestinal health.[2] Insulin sensitivity is influenced by the sensitivity of the gut microbiota, which is associated with diabetes and other disorders. The skin's microbiome is influenced by a person's age, genetics, lifestyle, cleanliness and surroundings. An imbalance in the composition and functional capacity of the microbiota is known

as dysbiosis and it has been linked to major health problems like IBD and diabetes. These include inflammation brought on by a breakdown in gut homeostasis [3] and infections caused by opportunistic pathogens like *Clostridium difficile* as a result of the microbiota's diminished ability to provide protection.[4]

Significance

- Melli reviewed in his study that children who experience allergies later in life have lower counts of *Bifidobacterium adolescentis, Bifidobacterium bifidum* and *Lactobacillus spp* and higher counts of *Bacteroidaceae* and anaerobic bacteria.[5] Studies on the microbiome have consistently revealed that these organisms interact with and break down external pollutants, including pesticides, ochratoxins, heavy metals, polycyclic aromatic hydrocarbons, organic compounds and plastic monomersIn the bladder, toxins that the kidney removes from the bloodstream following renal filtration act as substrates and foster an environment that allows the urinary tract microbiota to deactivate dangerous substances.
- Alterations in the gut microbiota can affect insulin sensitivity and contribute to diabetes.[6] The skin microbiome regulates immune responses and preserves the skin barrier to protect against infections and inflammatory skin diseases like psoriasis and eczema.[7] Probiotics, or good bacteria and prebiotics or food sources for beneficial bacteria can change the microbiome and potentially cure or ameliorate several illnesses, from gastrointestinal disorders to mental health problems.



Fig 1: Role of Microbiome in health and diseases

Early research to modern initiatives

The first indication that microorganisms are a part of the human system was discovered in the mid-1880s when Austrian pediatrician Theodor Escherich discovered a bacterium known as *Escherichia coli* in the intestinal flora of both healthy and sick infants. The number of microorganisms found inside human bodies has increased over time. *Veillonella parvula* for instance, was identified in the upper respiratory tract, digestive tract, oral cavity and urine in 1898. *Bifidobacteria* were discovered to be present in the gut flora in the 1900s. Over the 20th century, components of the human microbiota have been discovered and isolated from the skin, nasal passages, oral cavities, urogenital tract and gastrointestinal tract. The term 'microbiome' was introduced by Lederberg and McCray in 2001 to describe the community of microorganism inhabiting the human body.[8][9] The term "microbiome" refers to the ecological community of pathogenic, commensal and symbiotic microorganisms that inhabit our bodily area. After the Human Microbiome Project (HMP), a multinational endeavor to characterize the microbial communities in the human body and determine each microorganism's role in health and disease was initiated in 2007, the human microbiome rapidly increased.[10]

Microbiome development and composition

- Pregnant women have different vaginal microbiomes from the general population, but the makeup of the community determines how stable it is.[11] Pregnancy generally results in a shift toward community structures dominated by *Lactobacillus* and a loss of microbial diversity within the vaginal community. The developing baby may benefit from the increased *Lactobacillus* as well. Communities dominated by *Lactobacillus* provide protection against bacterial vaginosis [12], a vaginal microbiome defect linked to an increased risk of preterm birth.

- The microbiota within the gut lumen differed greatly from the bacteria that adhered to and encircled the epithelium because the gut contained numerous microenvironments. For example, the feces contained members of every genus known to science: *Bacteroides*, *Bifidobacterium, Streptococcus*, *Enterococcus, Clostridium, Lactobacillus*, and *Ruminococcus*. This indicated that the luminal community was well represented. In contrast, only *Clostridium, Lactobacillus* and *Enterococcus* were found in the mucus layer and epithelial crypts of the small intestine.[13]

Methods of study

Developing various experimental techniques and analytical technologies related to the microbiome has greatly benefited research on the microbiome in aging. Metatranscriptomics, metagenomics, and marker gene analyses are commonly employed in the analysis of microbiome data.[14]

Marker gene analysis

Marker gene analysis is a fundamental approach for identifying microbial diversity within a sample. Due to the multiple microenvironments the gut contained, the microbiota within the lumen of the gut was very different from the bacteria that clung to and surrounded the epithelium. Internal transcribed spacer or ITS is used for fungi, whereas 16S rDNA PCR amplification is commonly used for bacteria and archaea. Marker gene analysis is a quick, simple and affordable technique. PhyloChip is a further 16S rRNA gene-based method for tracking microbial communities. This microarray-based method looks at all nine variable regions of the 16S rRNA gene.[15]

Metagenomics

Handelsman et al. first introduced the concept of metagenomics, which involves sequencing genetic material directly from environmental samples. The technique the authors describe as "functional metagenomics" involves cloning random environmental DNA fragments into a suitable vector to preserve surrogate hosts. This enables functional screening and the search for functional improvements in surrogate hosts.[16]

Shotgun metagenomics

- These methods identify every microbial genome present in a sample by using untargeted sequencing techniques. The full repertoire of genetic information that can be extracted from a microbiome sample allows researchers to study bacteria, fungi, DNA viruses and other microbes; however, this process depends on reference genomes and scientific understanding. [17]
- Metagenomic shotgun assemblies can be created using reference genomes as a basis, from scratch or as a combination of the two. Short read data can be joined by overlapping reads, just like whole genome sequencing and utilized to build contigs (overlap, layout, consensus assembly). Nevertheless, this method is unfeasible due to its high computational requirements. MEGAHIT, MetaVelvet, IDBAUD and metaSPAdes are software tools for efficient de novo assembly. [18]

Metatranscriptomics

- Assessments of the expression activities of these organisms are made possible by selectively capturing the RNA transcribed from microbial cells. Illuminating sequencing techniques, particularly the HiSeq or NovaSeq families of instruments because of their high throughput and low cost per base, are the mainstay of shotgun metagenomics and metatranscriptomic techniques.
- Total RNA isolation from the microbiome sample, RNA enrichment, fragmentation, cDNA synthesis and transcriptome library preparation for sequencing are all steps in a typical workflow. [19]

Metabolomics

- The study of metabolites produced by microbiota and their interactions with host metabolism and microbiota is the main goal of metabolomics analyses. These techniques are frequently used to quantify small molecules, including host and bacterial metabolism intermediates, antibiotics and antibiotic products. Mass spectrometry is frequently used in metabolomics to identify recognized metabolites.[20]

Challenges

Complexity and Diversity

A wide range of microbial species interacts in complex ways within the remarkably diverse and complex microbiome. It is difficult to comprehend how various microbes interact with their host and with one another. Research on human microbiomes raises questions about ethics and privacy, particularly about the use and sharing of personal data. It is imperative to secure participant data and acquire informed consent. Individual Variability in Drug Response (IVDR) refers to differences in how people react to the same medication. Just as individuals have unique fingerprints, their bodies process drugs differently due to factors like genetics, age, diet, lifestyle,

coexisting medical conditions, and even the composition of their gut microbiome. Individual differences in the gut microbiota may impact drug-microbiota interactions.[21]

Technical Difficulties

Primer Selection in 16S rRNA Profiling

A key limitation of 16S rRNA sequencing—the gold standard for analyzing microbial diversity—is the choice of primers targeting specific regions (V1–V9) of the 16S gene. Primer selection significantly impacts results: studies show that using primers for shorter regions (e.g., V3 alone) often underestimates species richness, while targeting broader regions (e.g., V1–V2) may introduce technical artifacts. For example, longer amplicons (DNA fragments) sequenced using Illumina's paired-end 250-bp chemistry can produce overlapping low-quality sequences, artificially inflating diversity measurements. Thus, researchers must carefully balance primer selection with their study goals to minimize biases in microbial community analyses.[22]

Identifying Causality

The inherent diversity of the microbiome, which varies among individuals due to genetics, epigenetics, and environmental factors, makes identifying persistent patterns more difficult. Fecal microbiota transplantation (FMT) is a procedure where a patient receives fecal matter from a healthy donor, typically in capsule form, to restore gut microbial balance.

Human gut microbiota is injected into mice to create research models known as HMAMMs (Human Microbiota-Associated Murine Models). Through this method, scientists can examine the human gut microbiome in a controlled setting and see how it affects both health and disease and interacts with the host, in this case, mice. The risk of severe infections linked to FMT and the notable differences between humans and mice, which make it challenging to precisely replicate human microbial communities in mouse models, are obstacles to experimental approaches for establishing causality.[23]

Challenges in converting microbiome studies into medicinal uses

The incomplete depiction of the human microbiome in animal models presents an additional obstacle to proving causation in microbiome research. There can be significant differences between the microbiomes of humans and the animals used in in vivo research. An analysis of the gut microbiome revealed that certain human microbiota do not colonize animal models and that rodent models have a distinct microbiota that is not found in human models.[24]

Microbiome and health

The role of the gut microbiota in metabolism

- The gut microbiota is capable of carrying out a range of metabolic tasks that humans are either incapable of performing or only partially able to perform due to their significantly higher gene-encoding capacity compared to humans. The bacteria in the gut are capable of synthesizing all amino acids, essential and non-essential, as well as producing a wide range of vitamins and bio-converting bile.[25]
- The microbiome provides the necessary metabolic pathways for the breakdown of nondigestible carbohydrates, including alcohols and sugars from diets that are not absorbed, some oligosaccharides that are difficult to digest, and large polysaccharides like gums, resistant starches, cellulose, hemicellulose, and pectin.[26]
- Additionally, it supplies the energy and nutrients needed for bacterial growth and multiplication. This role gives the host an energy source and absorbable substrates. One of the colon's main sources of energy is the metabolism of carbohydrates.[27]

Immune system and host defense

- Pathogenic bacteria can enter intestinal epithelial cells through attachment sites on host cells. It has been observed from in vitro studies that nonpathogenic bacteria fight for these attachment sites on the periphery of the intestinal epithelial cells, preventing the entry of pathogenic, invasive bacteria. From their structural elements to their functional roles, bacteria were essential to the early development of the gut-mucosal immune system.
- Their continued importance to the system's functioning does not diminish as it advances. Studies have revealed differences in the microbial makeup of the intestines between young children with and without allergies. The intestinal microbiota is thought to stimulate and train the immune system to respond proportionately to all antigens. Early variations in the gut microbiota's composition can lead to an immune system that is ill-trained and frequently overreacts to antigens.[28]

Skin microbiome

- *Propionibacterium* acne, a bacterium that causes acne and helps to maintain healthy skin, is found in hair follicles. Different *Streptococcus* species live on different skin surfaces, supporting the equilibrium of the skin microbiome. To shield the skin from dangerous bacteria, skin-resident epidermidis *staphylococcus* fills voids and creates antimicrobial substances.
- A particular kind of fungal, these yeasts are a common part of the skin flora and aid in the digestion of fats. Occasionally, they could overgrow and exacerbate skin conditions like dandruff or seborrheic dermatitis. *Human papillomavirus* (HPV)- Warts and other skin infections have been connected to various HPV strains.[28]

Oral microbiome

- The term refers to the group of microorganisms that reside in the mouth, which includes viruses, bacteria, fungi and protozoa. The diversity of the microbial community significantly affects oral health in several ways, including: The bacteria *Streptococcus mutans* is the main thing behind dental caries or cavities. The acids produced when sugars are broken down can erode dental enamel.
- *Porphyromonas gingivalis* is linked to periodontal disease. This bacterium is well-known for its ability to irritate and degrade gum tissue. *Fusobacterium nucleatum* is a bacterium that has been connected to the development of periodontal disease and that can help other pathogens settle in the area. *Lactobacillus* species bacteria are frequently found in the mouth and use their ability to produce lactic acid to compete with pathogenic microorganisms for a balanced environment. *Candida albicans* is usually found in the mouth.
- This yeast has the potential to overgrow when oral thrush occurs, especially in people who wear dentures or have compromised immune systems. The *Human herpesvirus* is capable of causing cold sores and other oral herpes. The virus can also persist and recur in the mouth. Research on the *human papillomavirus* (HPV) has linked the development of oral cancer to specific HPV strains that are common in the oral cavity.[28]

Microbiome and diseases

There is a great deal of interest in using the microbiome for targeted therapeutics because of the implications of this research for human health, including links between the microbiome and drug metabolism, obesity, neurological diseases, cancer and more. With the advent of microbiome-directed therapies, the standard of care for *Clostridium difficile* infections has already begun to change due to the success of fecal microbiota transplants. Some evidence suggests that oral microbes may relocate into atherosclerotic plaques as a result of atherosclerosis. Plaques may also be influenced by gut lipid metabolism mediated by microbes.[29]

Table 1: Role of microbiome in diseases

SI. NO	Disease/ Condition	Link between diseases	Ref No
1.	**Autism**	Children with autism and neurotypical controls have different gut microbial communities, though there are some discrepancies. Mice with an autism phenotype are caused by microbial metabolites produced by their mothers.	[30]
2.	**Cardiovascular disease**	Trimethylamine-N-oxide levels in plasma and the risk of cardiovascular disease (with genetic predisposition) are correlated with diet and gut microbiome.	[32]
3.	**Cystic fibrosis**	*Pseudomonas aeruginosa* strains that are hypermutable are frequently responsible for persistent lung infections associated with this disease.	[33]
4.	**Depression**	When microbiota from people with major depressive disorder were transplanted into germ-free mice, the mice developed signs of depression. Changes in the metabolism of carbohydrates in the microbiome and hippocampal regions are linked to these symptoms.	[31]
5.	**Diabetes Type 1**	Although low-dose antibiotics increase susceptibility, the microbiome is necessary for the development of diabetes in mouse models. Though they occur before the disease manifests clinically, changes in microbial development indicate the course of the illness.	[35]
6.	**Diabetes Type 2**	Patients with this type of diabetes have lower blood levels of bacterial lipopolysaccharide.	[36]

7.	**Parkinson's disease**	In genetically predisposed people, the microbiome may accelerate the development of Parkinson's disease.	[37]
8.	**Rheumatoid arthritis**	Patients with RA exhibit altered oral and gut microbiomes. Additionally, they have increased oral bacterial translocation in the gut, which is partially corrected by treatment.	[38]
9.	**Inflammatory bowel disease**	Variations in microbial, environmental, and genetic factors are the main causes of gut inflammation. Initial episodes of ulceration may be aided by adherent enterobacteria.	[39]
10.	**Irritable bowel syndrome**	Individuals with this condition exhibit alterations in the mucosa and luminal gut microbiota, though it is unclear what causes them.	[40]

Role of microbiota in drug response

Microbial role in drug activation

- The hydrolytic enzyme β-glucosidase is exclusively found in the gut microbiota. When it releases glucose from glucosides, aglycones are created; some of these aglycones are even more dangerous than the glucosides they are linked to. This mechanism is especially common when gut microbes are breaking down components of phytomedicines.
- The principal bioactive component of *Armeniacae* semen, amygdalin, is broken down by the microbial β-glucosidase to yield glucose and mandelonitrile, the latter of which becomes toxic in the presence of amygdalin.[41] The nitro benzodiazepine nitrazepam is converted by nitroductases produced by the microbiota and liver into the metabolite 7-aminonitrazepam, which is responsible for nitrazepam-induced teratogenicity [42].

Microbial role in drug reactivation

- The mice's liver and gut microbiota metabolize mycophenolate mofetil (MMF) in conjunction with irinotecan via the same metabolic pathway. To be effective, it works as a prodrug that is hydrolyzed to mycophenolic acid (MPA), which is subsequently further converted to glucuronized MPA (MPAG) by hepatic enzymes.
- Urine removes most MPAG, but 10% finds its way into the digestive tract, where the gut microbial β glucuronidase transforms it back into MPA. MMF-induced colonic inflammation is associated with this accumulation of MPA in the colon.[42]

Role of the microbiome in drug inactivation

- The effects of drug inactivation by microbial metabolism differ from those of drug activation and reactivation, which frequently exacerbate drug toxicity. The inactivation of levodopa by the gut microbiota may account for decreased efficacy in the brain, increased side effects in peripheral tissues, and an increased dose schedule of levodopa treatment in Parkinson's disease.[43]
- Levodopa and carbidopa are administered simultaneously, along with an AADC inhibitor called (S)-α-Fluoromethyltyrosine, which suppresses *Enterococcus faecali* and *Eggerthella lenta* and blocks the microbial metabolism of levodopa to increase its bioavailability.[44]

Interaction between the immune system and microbiome

As a natural defense against pathogenic infection and commensal infiltration from the gut, the intestinal mucosa acts as an interface for two-way communication between the microbiome and the host immune system. In addition, pattern recognition receptors (PRRs) like TLRs (Toll-like receptors) and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) play a major role in mediating the crosstalk between the microbiome and the host innate immune system. These PRRs identify pathogen-associated molecular patterns (PAMPs) and trigger the innate immune system in response.[45]

Table: 2 Microbial roles in drug metabolism

Drug	Microbial Enzyme/Mechanism	Clinical Impact	Explanation
Levodopa	Decarboxylation by gut microbes	Reduced bioavailability	Gut microbial enzymes, such as tyrosine decarboxylase, convert levodopa to dopamine before it reaches the central nervous system, decreasing its therapeutic effect. Co-administration of enzyme inhibitors can mitigate this issue.

Mycophenolate mofetil	β-glucuronidase	Colonic inflammation	Mycophenolate mofetil (MMF) is metabolized into mycophenolic acid (MPA). Microbial β-glucuronidase reactivates MPA in the gut, leading to local toxicity and inflammation, often presenting as diarrhoea in patients.
Sulfasalazine	Azo reductase	Activation in the colon	Sulfasalazine is a prodrug activated in the colon by microbial azo reductase enzymes. This activation releases 5-aminosalicylic acid (5-ASA), which exerts anti-inflammatory effects critical for treating conditions like ulcerative colitis.
Digoxin	Reduction by *Eggerthella lenta*	Decreased efficacy	Specific gut bacteria reduce digoxin into inactive metabolites, resulting in diminished therapeutic outcomes. Manipulating gut microbiota with diet or antibiotics can enhance efficacy.
Irinotecan	β-glucuronidase	Severe gastrointestinal toxicity (diarrhoea)	Irinotecan is metabolized into SN-38, a potent anticancer agent, which is subsequently inactivated in the liver. Microbial β-glucuronidase reactivates SN-38 in the gut, causing toxicity. β-glucuronidase inhibitors are being studied to reduce this side effect.
Metformin	Modulation of gut microbiota composition	Improved glucose metabolism and insulin sensitivity	Metformin alters gut microbiota by increasing the abundance of beneficial bacteria like *Akkermansia muciniphila*, which contributes to its antidiabetic effects. This interaction enhances its therapeutic efficacy.
NSAIDs	Microbial biotransformation	Gastrointestinal side effects, including ulcers and inflammation	Gut microbes metabolize NSAIDs, producing reactive intermediates that can damage the intestinal lining, contributing to adverse effects like ulcers. Probiotics are being explored to mitigate these effects.
Rifampin	Induction of microbial resistance genes	Altered microbiome composition and reduced drug effectiveness	Prolonged use of rifampin influences gut microbial populations, leading to resistance development and changes in the microbiome, which may impact therapeutic outcomes.

Therapeutic applications

- There is now greater interest in the organism's potential therapeutic applications due to the numerous studies that demonstrate the importance of a healthy microbiota for human health and disease prevention. The early success of Fecal Microbial Transplantation (FMT) as a treatment for recurrent or resistant *Clostridium difficile*-induced colitis has led to a surge in interest in this approach.[46]
- Reversing the metabolic changes brought on by high-fat diets, such as insulin resistance, adipose tissue inflammation, fat mass gain and metabolic endotoxemia, oral administration of *Akkermansia muciniphila* increased gut colonization proportionately. Transferring organisms that had been killed by heat did not produce these effects. One of the uncommon bacterial genera whose ratios are connected to metabolic processes is *Akkermansia*. However, given the potential to alter metabolic phenotypes, patients with intestinal bacterial populations might benefit from treatment.[47]

Prebiotics

- Probiotics are live microorganisms that offer health benefits to their host when given in adequate quantities. They could help preserve or restore a balanced microbiota. Probiotic strains like *Lactobacillus plantarum* and *Bifidobacterium infantis* have been shown to relieve the symptoms of irritable bowel syndrome (IBS), including bloating and abdominal pain. Probiotics like *Saccharomyces boulardii* have

the potential to prevent and treat antibiotic-associated diarrhea because they support the restoration of the gut microbiota.[48]

- When indigestible food ingredients known as prebiotics are present, good gut bacteria are more developed and activated. By encouraging the development of advantageous bacteria and raising the frequency of stools, prebiotics like inulin and fructo-oligosaccharides (FOS) help to improve intestinal regularity. Prebiotics may help manage type II diabetes and other metabolic health issues by changing the makeup of the gut microbiota and improving insulin sensitivity.[46]

Fecal Microbiota Transplantation (FMT)

Restoring the patient's microbiome balance requires giving them feces from a healthy donor. Recurrent Clostridium Difficile infection (CDI) is a serious intestinal condition often resistant to traditional antibiotics. FMT is a helpful treatment for CDI. Research indicates that reintroducing a healthy microbiota through FMT can result in notable improvements in healing rates.[49]

Synbiotics enhance the growth and function of advantageous microorganisms by combining probiotics and prebiotics. *Lactobacillus* strains found in prebiotic fibers, such as insulin and synbiotic supplements, have been used to enhance the digestive system's health and function, potentially reducing symptoms of IBS and constipation. Microbiome-focused diets: foods high in fruits, vegetables and whole grains, as well as dietary fiber, can promote the growth of good gut bacteria and improve metabolic health. These diet plans lower the risk of cardiovascular disease, type 2 diabetes and obesity.[48]

Microbiome modification and mental health:

Probiotic strains that have been demonstrated to modify gut microbiota and inflammation, such as *Lactobacillus rhamnosus* and *Bifidobacterium longum*, may help reduce symptoms of anxiety and depression. According to preliminary research, probiotics and dietary modifications may help lessen gastrointestinal and behavioral symptoms in children diagnosed with autism spectrum disorder (ASD).

Everybody's microbiome can now be examined thanks to developments in sequencing technologies. By using this data, customized probiotics may be made, which could result in better medical outcomes for conditions like digestive system problems. It makes sense to create probiotics that are especially suited to a person's microbiome composition because every person's microbiome is so distinct. More effective treatments for ailments like digestive system disorders might result from these customized probiotics.[50]

Future directions

Personalized medicine and comprehensive microbiome profiling will be possible with the development of genomic and metagenomic technologies. As a result, each person may receive specialized treatments based on their unique microbiome composition, such as dietary recommendations, prebiotics and probiotics. [51]

Therapeutic Discovery Based on Microbiome

Phage therapy is a treatment that can eliminate pathogenic bacteria while leaving the beneficial microbiota intact e.g., targeting *C. difficile*. Viral vectors that specifically target bacteria are used in their operation. For infections that are resistant to antibiotics, this treatment strategy appears to be especially effective. Microbiome modulators: A variety of diseases can be treated with standard regimens that include medications and treatments designed to change the makeup or activity of microorganisms within the microbiome.[52]

The mental health and microbiome

Psychobiotics: More research will be done to determine how probiotics and other treatments that alter the microbiome impact mental health issues like depression, anxiety, and stress-related disorders. Creating "psychobiotics" that focus on gut-brain connections might be feasible. Axis of the Gut-Brain: With a better understanding of this relationship, new treatments and interventions targeting neuropsychiatric disorders via microbiome modulation will be developed.[50]

The Role of Environmental Microbiomes

Bioremediation Studying microbiomes will aid in bioremediation, which employs microorganisms to control waste and eliminate contaminants from the environment, enhancing environmental health and sustainability.[53]

Modern Technologies

Microbiome sequencing: As sequencing technologies advance, it will become possible to conduct more comprehensive and current analyses of microbiome diversity, functionality and dynamics. Advancements in AI and machine learning are enhancing microbiome analysis, and enabling predictive modeling, microbiota-based diagnostics, and personalized inventions. ML tools like QIIME2 or PICRUSt2 for microbiome analysis [54]

CONCLUSION

The review concludes that further research using both new and old technologies is needed to advance our knowledge of the human microbiome's role in human health and disease, as well as the development of new medications. Adopting new techniques created to investigate drug-microbiota interactions will surely result in a more thorough comprehension of the interaction between these intricate ecosystems and enable the development of creative, successful disease-treating approaches. Better integration of metagenomic, metabolomic, and metaproteomic techniques; improved characterization of viruses, parasites, and fungi; and better characterization of the therapeutic potential of genetically modified microbes are important future directions that will advance our mechanistic understanding of microbiome processes and/or benefit patients. Drug, microbiome, microbial enzymes and metabolites, drug metabolites and host toxicant responses are the microbial components that may be linked to influence drug toxicity. To comprehend the systemic relationship between the microbiome and drug toxicity, Studies on the gut microbiota have revealed the mechanisms behind these pancreatic disorders, providing information about their severity, prognosis and risk. Concerning each person's unique microbiome and condition, the microbiota presents a vast potential for personalized treatment.

REFERENCES

1. Kim M, Benayoun BA. The microbiome: an emerging key player in aging and longevity. *Translational medicine of aging*. 2020 Jan 1;4:103-16.
2. Bull MJ, Plummer NT. Part 2: treatments for chronic gastrointestinal disease and gut dysbiosis. *Integrative Medicine*: A Clinician's Journal. 2015 Feb;14(1):25.
3. Cheng L, Qi C, Zhuang H, Fu T, Zhang X. gut Disorder: a comprehensive database for dysbiosis of the gut microbiota in disorders and interventions. *Nucleic acids research*. 2020 Jan 8;48(D1):D554-60.
4. Green JE, Davis JA, Berk M, Hair C, Loughman A, Castle D, Athan E, Nierenberg AA, Cryan JF, Jacka F, Marx W. Efficacy and safety of fecal microbiota transplantation for the treatment of diseases other than Clostridium difficile infection: a systematic review and meta-analysis. *Gut microbes*. 2020 Nov 9;12(1):1854640.
5. Melli LC, do Carmo-Rodrigues MS, Araújo-Filho HB, Solé D, De Morais MB. Intestinal microbiota and allergic diseases: a systematic review. Allergologia et immunopathologia. 2016 Mar 1;44(2):177-88.
6. Zhou Y, Zhang Y, Lian X, Li F, Wang C, Zhu F, Qiu Y, Chen Y. Therapeutic target database update 2022: facilitating drug discovery with enriched comparative data of targeted agents. *Nucleic acids research*. 2022 Jan 7;50(D1):D1398-407.
7. SanMiguel A, Grice EA. Interactions between host factors and the skin microbiome. *Cellular and Molecular Life Sciences*. 2015 Apr;72:1499-515.
8. Hayes W, Sahu S. The Human Microbiome: History and Future: Microbiome. Journal of Pharmacy & Pharmaceutical Sciences. 2020 Oct 27;23:406-11.
9. Lederberg J, McCray AT. Ome SweetOmics--A genealogical treasury of words. *The scientist*. 2001 Apr 2;15(7):8-.
10. Romero R, Hassan SS, Gajer P, Tarca AL, Fadrosh DW, Nikita L, Galuppi M, Lamont RF, Chaemsaithong P, Miranda J, Chaiworapongsa T. The composition and stability of the vaginal microbiota of normal pregnant women is different from that of non-pregnant women. *Microbiome*. 2014 Dec;2:1-9.
11. MacIntyre DA, Chandiramani M, Lee YS, Kindinger L, Smith A, Angelopoulos N, Lehne B, Arulkumaran S, Brown R, Teoh TG, Holmes E. The vaginal microbiome during pregnancy and the postpartum period in a European population. Scientific reports. 2015 Mar 11;5(1):8988.
12. Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL, Karlebach S, Gorle R, Russell J, Tacket CO, Brotman RM. Vaginal microbiome of reproductive-age women. Proceedings of the National Academy of Sciences. 2011 Mar 15;108(supplement_1):4680-7.
13. Swidsinski A, Loening-Baucke V, Lochs H, Hale LP. Spatial organization of bacterial flora in normal and inflamed intestine: a fluorescence in situ hybridization study in mice. World journal of gastroenterology: WJG. 2005 Feb 2;11(8):1131.
14. Nelson TA, Holmes S, Alekseyenko AV, Shenoy M, DeSantis T, Wu CH, Andersen GL, Winston J, Sonnenburg J, Pasricha PJ, Spormann A. PhyloChip microarray analysis reveals altered gastrointestinal microbial communities in a rat model of colonic hypersensitivity. *Neurogastroenterology & Motility*. 2011 Feb;23(2):169-e42.
15. Handelsman J, Rondon MR, Brady SF, Clardy J, Goodman RM. Molecular biological access to the chemistry of unknown soil microbes: a new frontier for natural products. *Chemistry & biology*. 1998 Oct 1;5(10):R245-9.
16. Quince C, Walker AW, Simpson JT, Loman NJ, Segata N. Shotgun metagenomics, from sampling to analysis. Nature biotechnology. 2017 Sep;35(9):833-44.

17. Ayling M, Clark MD, Leggett RM. New approaches for metagenome assembly with short reads. Briefings in bioinformatics. 2020 Mar;21(2):584-94.
18. Bashiardes S, Zilberman-Schapira G, Elinav E. Use of metatranscriptomics in microbiome research. Bioinformatics and biology insights. 2016 Jan;10:BBI-S34610.
19. Lamichhane S, Sen P, Dickens AM, Orešič M, Bertram HC. Gut metabolome meets microbiome: A methodological perspective to understand the relationship between host and microbe. Methods. 2018 Oct 1;149:3-12.
20. Zierer J, Jackson MA, Kastenmüller G, Mangino M, Long T, Telenti A, Mohney RP, Small KS, Bell JT, Steves CJ, Valdes AM. The fecal metabolome as a functional readout of the gut microbiome. *Nature genetics*. 2018 Jun;50(6):790-5.
21. Seshadri S. Microbial communication via quorum sensing: influence and alteration of gut ecosystem. JSM Biochem Mol Biol. 2017;4(1):1020-3.
22. Brubaker L, Gourdine JP, Siddiqui NY, Holland A, Halverson T, Limeria R, Pride D, Ackerman L, Forster CS, Jacobs KM, Thomas-White KJ. Forming consensus to advance urobiome research. mSystems 6, e0137120. DOI. 2021;10:01371-20.
23. Walter J, Armet AM, Finlay BB, Shanahan F. Establishing or exaggerating causality for the gut microbiome: lessons from human microbiota-associated rodents. Cell. 2020 Jan 23;180(2):221-32.
24. Lv BM, Quan Y, Zhang HY. Causal inference in microbiome medicine: principles and applications. *Trends in microbiology*. 2021 Aug 1;29(8):736-46.
25. Surana NK, Kasper DL. Moving beyond microbiome-wide associations to causal microbe identification. Nature. 2017 Dec 14;552(7684):244-7.
26. Zhang L, Bahl MI, Roager HM, Fonvig CE, Hellgren LI, Frandsen HL, Pedersen O, Holm JC, Hansen T, Licht TR. Environmental spread of microbes impacts the development of metabolic phenotypes in mice transplanted with microbial communities from humans. The ISME journal. 2017 Mar;11(3):676-90.
27. Cummings JH, Pomare EW, Branch WJ, Naylor CP, MacFarlane G. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987 Oct 1;28(10):1221-7.
28. Guarner F, Malagelada JR. Gut flora in health and disease. The lancet. 200 Björkstén B, Sepp E, Julge K, Voor T, Mikelsaar M. Allergy development and the intestinal microflora during the first year of life. *Journal of allergy and clinical immunology*. 2001 Oct 1;108(4):516-20 Feb 8;361(9356):512-9.
29. Jonsson AL, Bäckhed F. Role of gut microbiota in atherosclerosis. Nature Reviews Cardiology. 2017 Feb;14(2):79-87.
30. Ding HT, Taur Y, Walkup JT. Gut microbiota and autism: key concepts and findings. Journal of autism and developmental disorders. 2017 Feb;47:480-9.
31. Hsiao EY, McBride SW, Hsien S, Sharon G, Hyde ER, McCue T, Codelli JA, Chow J, Reisman SE, Petrosino JF, Patterson PH. Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell. 2013 Dec 19;155(7):1451-63.
32. Tang WW, Hazen SL. The contributory role of gut microbiota in cardiovascular disease. The Journal of clinical investigation. 2014 Oct 1;124(10):4204-11.
33. Lynch SV, Bruce KD. The cystic fibrosis airway microbiome. Cold Spring Harbor perspectives in medicine. 2013 Mar 1;3(3):a009738.
34. Oliver A, Cantón R, Campo P, Baquero F, Blázquez J. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science. 2000 May 19;288(5469):1251-3.
35. Paun A, Yau C, Danska JS. The influence of the microbiome on type 1 diabetes. The Journal of Immunology. 2017 Jan 15;198(2):590-5.
36. Wang X, Xu X, Xia Y. Further analysis reveals new gut microbiome markers of type 2 diabetes mellitus. Antonie Van Leeuwenhoek. 2017 Mar;110(3):445-53.
37. Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, Challis C, Schretter CE, Rocha S, Gradinaru V, Chesselet MF. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease. Cell. 2016 Dec 1;167(6):1469-80.
38. Zhang X, Zhang D, Jia H, Feng Q, Wang D, Liang D, Wu X, Li J, Tang L, Li Y, Lan Z. The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nature medicine. 2015 Aug;21(8):895-905.
39. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014 May 1;146(6):1489-99.
40. Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan 1;62(1):159-76.
41. Takeno S, Sakai T. Involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction. Teratology. 1991 Aug;44(2):209-14.

42. Lamba V, Sangkuhl K, Sanghavi K, Fish A, Altman RB, Klein TE. PharmGKB summary: mycophenolic acid pathway. Pharmacogenetics and genomics. 2014 Jan 1;24(1):73-9.
43. van Kessel SP, Frye AK, El-Gendy AO, Castejon M, Keshavarzian A, van Dijk G, El Aidy S. Gut bacterial tyrosine decarboxylases restrict levels of levodopa in the treatment of Parkinson's disease. Nature communications. 2019 Jan 18;10(1):310.
44. Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science. 2019 Jun 14;364(6445):eaau6323.
45. Prajapati B, Kumar Jena P, Rajput P, Purandhar K, Seshadri S. Understanding and modulating the Toll like Receptors (TLRs) and NOD like Receptors (NLRs) cross talk in type 2 diabetes. Current diabetes reviews. 2014 May 1;10(3):190-200.
46. Borody TJ, Campbell J. Fecal microbiota transplantation: current status and future directions. Expert review of gastroenterology & hepatology. 2011 Nov 1;5(6):653-5.
47. Nieuwdorp M, Gilijamse PW, Pai N, Kaplan LM. Role of the microbiome in energy regulation and metabolism. Gastroenterology. 2014 May 1;146(6):1525-33
48. Swanson KS, Gibson GR, Hutkins R, Reimer RA, Reid G, Verbeke K, Scott KP, Holscher HD, Azad MB, Delzenne NM, Sanders ME. The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics. Nature Reviews Gastroenterology & Hepatology. 2020 Nov;17(11):687-701
49. Wilson M. Microbial inhabitants of humans: their ecology and role in health and disease. Cambridge University Press; 2005.
50. Bastiaanssen TF, Cryan JF. The microbiota-gut-brain axis in mental health and medication response: parsing directionality and causality. *International Journal of Neuropsychopharmacology*. 2021 Mar 1;24(3):216-20.
51. Herremans KM, Riner AN, Cameron ME, McKinley KL, Triplett EW, Hughes SJ, Trevino JG. The oral microbiome, pancreatic cancer and human diversity in the age of precision medicine. Microbiome. 2022 Jun 15;10(1):93.
52. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):162-173. doi: 10.4292/wjgpt.v8.i3.162. PMID: 28828194; PMCID: PMC5547374
53. Dai Z, Sevillano-Rivera MC, Calus ST, Bautista-de Los Santos QM, Eren AM, Van Der Wielen PW, Ijaz UZ, Pinto AJ. Disinfection exhibits systematic impacts on the drinking water microbiome. Microbiome. 2020 Dec;8:1-9.
54. Wu Y, Zhuang J, Song Y, Gao X, Chu J, Han S. Advances in single-cell sequencing technology in microbiome research. Genes Dis. 2023 Sep 28;11(4):101129. doi: 10.1016/j.gendis.2023.101129. PMID: 38545125; PMCID: PMC10965480.